Study Finds Association Between Caffeinated Coffee, Tea Consumption and Lower Dementia Risk

A new study published in a peer-reviewed journal has reported an association between the consumption of caffeinated coffee and tea and a decreased risk of developing dementia. Researchers analyzed data from over 10,000 participants aged 50 and older, tracking their beverage intake and cognitive health outcomes over a 14-year period.

The study found that individuals who consumed at least three cups of caffeinated coffee or tea daily had a 20-30% lower incidence of dementia compared to non-consumers.

The research was conducted by a team from the University of South Florida and the University of Miami, utilizing data from the UK Biobank. Participants' coffee and tea habits were self-reported at the start of the study, with dementia diagnoses verified through medical records and cognitive assessments.

The study controlled for factors such as age, sex, smoking status, physical activity, and diet to isolate the effects of caffeine intake.

Limitations Caffeine, the active compound in coffee and tea, was identified as the likely factor contributing to the observed risk reduction.

The study did not find similar benefits from decaffeinated versions of these beverages. Authors noted that the observational design limits conclusions about direct causation, as other lifestyle variables could influence results. Dementia affects millions worldwide, with Alzheimer's disease as the most common form.

6 million by 2040. The study's findings add to existing evidence on lifestyle factors that may influence cognitive health, including diet and exercise.

Health organizations, such as the Alzheimer's Society, have welcomed the research but emphasize moderation in caffeine intake due to potential side effects like insomnia or increased heart rate.

The study suggests that moderate consumption—around 3-4 cups per day—could be incorporated into daily routines for those without contraindications. Further randomized controlled trials are recommended to validate these associations and explore mechanisms at the biological level.

The research was funded by the National Institutes of Health and published in the Journal of Alzheimer's Disease on October 15, 2023.

It builds on prior studies linking caffeine to neuroprotection, such as reduced amyloid plaque formation in the brain. Affected groups include older adults at risk for cognitive decline, with potential benefits for global aging populations.